Chronic News and Research

RSS

New public health tool to identify all Tier 1 candidates for H1N1 vaccination

Practice Fusion Inc. (www.practicefusion.com), the free, web-based electronic health record (EHR) for physicians, today implemented a first-of-its-kind tool that allows its physician-users to immediately and accurately identify all Tier 1 candidates for H1N1 vaccination from their patient populations using criteria published by the Centers for Disease Control and Prevention (CDC).

21 Oct 2009

CMSA and DMAA to promote fully-connected health care system to improve clinical and financial outcomes

The Case Management Society of America (CMSA) and DMAA: The Care Continuum Alliance (DMAA) are working together to strengthen and define the relationship between health care "case management" and "population health management" interventions.

21 Oct 2009

CCS is the largest funder of childhood and adolescent cancer research in the charitable sector

A new report released today by the Canadian Cancer Research Alliance reveals that the Canadian Cancer Society (CCS) is the largest funder of childhood and adolescent cancer research in the charitable sector, contributing 23 per cent of total funding. The B.C. and Yukon division of the CCS contributes more than 40 per cent of that funding through donations from Cops for Cancer.

21 Oct 2009

Logical Therapeutics to present its clinical study results on LT-NS001

Logical Therapeutics, Inc. (Logical), a biopharmaceutical company focused on developing products that treat medical conditions associated with inflammation, has been selected to present the results of its clinical study comparing the gastrointestinal (GI) safety of its lead product LT-NS001, vs. naproxen at the American College of Gastroenterology's (ACG) Annual Scientific Meeting on October 27, 2009.

21 Oct 2009

People living with diabetes to increase up to 435 million by 2030

The latest International Diabetes Federation (IDF) data reveals that over 285 million people worldwide now live with diabetes and this number will explode to 435 million by 2030. This staggering figure does not capture the toll the disease takes on the individual. Unlike other diseases, people with diabetes are responsible for 95% of their own care and many are doing so without the proper skills and knowledge to do so.

21 Oct 2009

Americans who believe in equality are impulsive shoppers, says new study

A new study from Rice University's Jones Graduate School of Business finds that Americans who believe in equality are more-impulsive shoppers. And it has implications for how to market products differently in countries where shoppers are more likely to buy on impulse.

21 Oct 2009

School meal programs should adopt new set of nutrient targets, says IOM

The National School Lunch Program and the School Breakfast Program should adopt a new set of nutrient targets and standards for menu planning, says a new report from the Institute of Medicine.

21 Oct 2009

Apotex to market Hisamitsu's Fentanyl Transdermal System for chronic pain management

Apotex Corp announced today that it has signed an exclusive distribution agreement with Hisamitsu Pharmaceutical Company of Japan. Apotex will sell to the U.S. healthcare market, Hisamitsu's recently FDA approved matrix Fentanyl Transdermal System for the management of chronic pain.

21 Oct 2009

Massachusetts seeks to cut increase in small business health care costs

Today's state news covers access to care issues in Florida and California, a new proposal to review premiums charged to small business, and the potential flaws of Ohio's nursing home payment plan.

21 Oct 2009

New cutting edge nerve procedure relieves migraine permanently

The Plastic Surgery Center today announced that a 57-year-old Plainfield man reports he is free of constant headache pain after undergoing a new cutting edge nerve procedure to permanently eliminate pain caused by migraines. The procedure was performed by plastic and reconstructive surgeon Dr. Matthew Kaufman, of the Plastic Surgery Center in New Jersey on August 4, 2009.

21 Oct 2009

Patients with chronic hepatitis C can benefit by drinking coffee

Patients with chronic hepatitis C and advanced liver disease who drink three or more cups of coffee per day have a 53% lower risk of liver disease progression than non-coffee drinkers according to a new study led by Neal Freedman, Ph.D., MPH, from the National Cancer Institute (NCI).

20 Oct 2009

ImPACKD calls for raising awareness about the risks of calcium overuse in CKD patients

Most Canadians living with CKD have likely never spoken with their physicians about calcium and the serious health risks associated with its overuse. This is why Improving Patient Advocacy in Chronic Kidney Disease (ImPACKD), a group of CKD patients and caregivers committed to raising awareness about the risks of calcium overuse, is starting the conversation about the importance of knowing the limits and keeping them in check.

20 Oct 2009

Presentation highlights the administration of autologous stem cells for treating spinal cord injury

DaVinci Biosciences LLC, of Costa Mesa, CA, announced today the presentation of their safety and feasibility study demonstrating the administration of autologous bone marrow derived stem cells for the treatment of acute and chronic spinal cord injury at Neuroscience 2009, Society for Neuroscience's 39th Annual Meeting, to be held at McCormick Convention Center in Chicago, IL.

20 Oct 2009

Waters presents a new video on its UPLC Systems, Mass Spectrometers and SDMS software solutions

Waters Corporation has posted a new version of its online video showcase featuring compelling interviews with more than 50 scientists, development partners, and product experts in the fields of pharmaceutical discovery and development, food safety, environmental analysis, sports medicine, disease research and clinical toxicology and clinical research.

20 Oct 2009

Two high blood pressure medicines effective in treating stable ischemic heart disease

Two medications commonly used to treat high blood pressure appear to be effective in treating a common type of heart disease known as stable ischemic heart disease, according to a new comparative effectiveness review funded by HHS' Agency for Healthcare Research and Quality.

20 Oct 2009

Novartis' Tasigna capsules meets primary endpoint in comparison trial with Gleevec

Novartis announced today that Tasigna (nilotinib) 200 mg capsules met its primary endpoint in the first head-to-head comparison with the company's groundbreaking drug Gleevec (imatinib mesylate) tablets*. Tasigna produced faster and deeper responses than Gleevec when given as first-line therapy for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. Tasigna was well tolerated in the study.

20 Oct 2009

Repligen completes patient treatment in its Phase 3 RG1068 clinical trial

Repligen Corporation reported today that it has completed patient treatment in its Phase 3 clinical trial of RG1068, synthetic human secretin, in magnetic resonance imaging (MRI) of the pancreas. The study is designed to assess the sensitivity and specificity of RG1068 in conjunction with MRI for the detection of pancreatic duct abnormalities compared to MRI alone.

20 Oct 2009

Testicular cancer survivors at risk of effective treatment

Testicular cancer survivors can face an increased risk of long-term illness, not because of the malignancy, but the highly effective treatment they receive, according to a study in the urology journal BJUI.

20 Oct 2009

Stemedica completes pre-IND meeting with the FDA concerning allogeneic mesenchymal bone marrow cells

Stemedica Cell Technologies, Inc., a world leader in stem cell research and manufacturing, announced that it completed its pre-IND meeting with the U.S. Food and Drug Administration (FDA) regarding a proposed IND (Investigative New Drug) to evaluate the safety and efficacy of Stemedica's high potency proprietary allogeneic mesenchymal bone marrow-derived stem cells (adult human) as a treatment for ischemic stroke.

20 Oct 2009

Menarini granted exclusive European licence rights to Ipsen's Adenuric

Ipsen, an innovation-driven global specialty pharmaceutical group, announced an agreement whereby Ipsen grants the Menarini Group the exclusive licence rights to Adenuric® (febuxostat) in 41 countries. Ipsen retains co-promotion rights for Adenuric® in France.

20 Oct 2009

Chronic News and Research

New public health tool to identify all Tier 1 candidates for H1N1 vaccination

CMSA and DMAA to promote fully-connected health care system to improve clinical and financial outcomes

CCS is the largest funder of childhood and adolescent cancer research in the charitable sector

Logical Therapeutics to present its clinical study results on LT-NS001

People living with diabetes to increase up to 435 million by 2030

Americans who believe in equality are impulsive shoppers, says new study

School meal programs should adopt new set of nutrient targets, says IOM

Apotex to market Hisamitsu's Fentanyl Transdermal System for chronic pain management

Massachusetts seeks to cut increase in small business health care costs

New cutting edge nerve procedure relieves migraine permanently

Patients with chronic hepatitis C can benefit by drinking coffee

ImPACKD calls for raising awareness about the risks of calcium overuse in CKD patients

Presentation highlights the administration of autologous stem cells for treating spinal cord injury

Waters presents a new video on its UPLC Systems, Mass Spectrometers and SDMS software solutions

Two high blood pressure medicines effective in treating stable ischemic heart disease

Novartis' Tasigna capsules meets primary endpoint in comparison trial with Gleevec

Repligen completes patient treatment in its Phase 3 RG1068 clinical trial

Testicular cancer survivors at risk of effective treatment

Stemedica completes pre-IND meeting with the FDA concerning allogeneic mesenchymal bone marrow cells

Menarini granted exclusive European licence rights to Ipsen's Adenuric

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News